Nordic Nanovector strengthens management team to prepare for its next phase

Nordic Nanovector AS strengthens its management team by appointing two highly experienced executives to key leadership roles. The executives will play pivotal roles as the Company continues to explore different avenues to leverage its proprietary targeting technology for optimal long-term value creation.

Effective November 3rd 2014, Nordic Nanovector announces the appointment of 2 new executive officers: Cristina Oliva, MD as Chief Medical Officer and Marco Renoldi, MD as Chief Business Officer, both reporting to Mr. Luigi Costa, Chief Executive Officer.

Chief Medical Officer Cristina Oliva, MD, brings 20 years of clinical and research management experience from leading institutions and companies. Recently she served as Vice President of Global Development, Oncology at Shionogi Ltd. and previously she held similar positions in leading companies such as Takeda and GlaxoSmithKline.
Cristina Oliva holds a Degree in Medicine and Surgery from the University of Genoa, Italy, and is certified by the General Medical Council (GMC), Board Certified in Medicine & Surgery and Oncology in Italy. She has authored and co-authored over 100 publications, abstracts and papers.
Ms. Oliva will lead the definition and the execution of BetalutinTM’s clinical development programs to ensure the optimization of its full market potential as well as a timely access to market.

Chief Business Officer Marco Renoldi, MD is an international pharmaceutical and biotech business leader, with an impressive track record of commercial and financial results over 28 years of industry experience. He combines scientific, business and commercialization expertise. Mr. Renoldi has developed product lines and businesses, including start-ups, for established and innovative companies such as Novartis, Searle/Pharmacia, Amgen and Shionogi.
Marco Renoldi holds a medical degree and post-graduate studies in Child Neuropsychiatry from the University of Milan, and an MBA from Fondazione Istituto Dirigenti Italiani, also in Milan. In Nordic Nanovector, Mr. Renoldi is responsible for the development and execution of the Company’s international growth strategy through the definition of value drivers and the selection of the most appropriate business models. In addition, Mr. Renoldi will be responsible for the definition of market access and pricing strategy and will lead the Company’s Business Development initiatives.

In addition to the above-mentioned appointments, the Company announces its new leadership organization:

Jan A. Alfheim is appointed Chief Operations Officer with responsibility for the development and the execution of the Company’s manufacturing and supply chain strategy and for the Company’s technical partnership activities. With his previous experience as the Company’s CEO, Mr. Alfheim will continue to play an important role at Nordic Nanovector and support its transition to its new phase.

Jostein Dahle, PhD is confirmed as Chief Scientific Officer with responsibility for all the Company pre-clinical initiatives and for the development of the Company’s pipeline. Mr. Dahle has over 15 years of experience in cancer research. Mr. Dahle, previous CEO of Nordic Nanovector, led the Radioimmunotherapy group at the Institute for Cancer Research at the Norwegian Radium Hospital.

Anniken Hagen is confirmed as Head of Quality Assurance, with responsibility for the Company’s quality assurance and policies, GMP compliance and product quality assurance. Ms. Hagen has more than 20 years of experience in the pharmaceutical industry, most of which dealing with radiopharmaceuticals. In her previous position, she was Head of QA, responsible for building facilities and QMS for GMP manufacturing of positron emission radiopharmaceuticals (PET) at Oslo University Hospital.

Tone Kvåle is confirmed as Chief Financial Officer with responsibility for financial strategy and accounting as well as for the relationship with all key investment institutions. Ms. Kvåle brings over 16 years of experience in the biotech industry. Prior to joining Nordic Nanovector, she was CFO at NorDiag ASA. Previously, she held senior management positions at Kavli Holding AS, Invitrogen/Life Technologies, US and Dynal Biotech AS.

– Nordic Nanovector has reached a stage where we see the need to reinforce our talent base in order to fully exploit our global business opportunities. As a biotech company with considerable aspirations, the Company intends to take full advantage of the significant experience in commercial development and clinical oncology represented by the recent additions to the leadership team, as well as of the existing capabilities in a structured organization. I am confident that with a team of highly capable executives will help support and accelerate the development of Nordic Nanovector’s product pipeline, says Luigi Costa, Chief Executive Officer.


Luigi Costa, Chief Executive Officer                    

Cell: (+41) 79 124 8601                


Tone Kvåle, Chief Financial Officer

Cell:       (+47) 91 51 95 76


About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).


About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at